This could potentially imply an underlying genetic risk with implications on clinical need, such as that seen in EGFR mutations and lung cancers in East Asian patients.35 Additional study is needed though, as there are conflicting observations in the existing literature with other studies supporting both increases and decreases in the prevalence of MTAP-loss in East Asian patients.36,37. This evidence concerns the gene MTAP and lung cancer.